Physician profile
Daniel R Marshall
NPI 1861583486
$1,793.06
in general payments reported to CMS, 2019-2025
21 companies · $367 in 2025
The $367 reported for 2025 was less than what a typical Mohs-Micrographic Surgery provider received nationally (typical 2025 total: $462).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $352 · 2020: $129 · 2021: $160 · 2022: $193 · 2023: $324 · 2024: $267 · 2025: $367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $958.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $958.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $454.34 | 2019-2025 | |
| Lilly USA, LLC | $368.66 | 2019-2025 | Taltz, Ebglyss, Olumiant |
| Novartis Pharmaceuticals Corporation | $166.62 | 2019-2025 | |
| Ucb, INC. | $126.10 | 2019-2025 | Bimzelx, Cimzia |
| Biofrontera INC. | $91.24 | 2019-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Dermavant Sciences, INC. | $85.85 | 2023-2024 | Vtama |
| Neurocrine Biosciences, INC. | $67.33 | 2025 | |
| Amgen INC. | $57.96 | 2020-2024 | Otezla |
| Galderma Laboratories, L.P. | $55.15 | 2021-2025 | Nemluvio |
| Janssen Biotech, INC. | $55.08 | 2019-2024 | Tremfya |
| Sun Pharmaceutical Industries INC. | $36.55 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $31.54 | 2023-2025 | Sotyktu |
| Bioxcel Therapeutics, INC. | $30.88 | 2023 | Igalmi |
| Merck Sharp & Dohme LLC | $28.24 | 2019 | |
| Incyte Corporation | $28.03 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $26.06 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $25.73 | 2019 | |
| Genzyme Corporation | $24.91 | 2024 | |
| Dermira, INC. | $12.68 | 2021 | |
| Genentech USA, INC. | $11.92 | 2019 | |
| Organon LLC | $8.19 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Marshall listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.